

Title (en)
NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE ANALOGS, ANTAGONISTS, AND FORMULATIONS THEREOF

Title (de)
NANOPARTIKEL- UND POLYMERFORMULIERUNGEN FÜR THYROIDHORMONANALOGE, ANTAGONISTEN DAFÜR UND FORMULIERUNGEN DARAUSS

Title (fr)
NANOPARTICULE ET FORMES POLYMÈRES D'ANALOGUES ET D'ANTAGONISTES DE L'HORMONE THYROÏDIENNE ET LEURS FORMULATIONS

Publication
EP 2018186 A2 20090128 (EN)

Application
EP 07867073 A 20070411

Priority
• US 2007009026 W 20070411
• US 79123506 P 20060411
• US 83174006 P 20060717
• US 85645006 P 20061102
• US 66304707 A 20070315

Abstract (en)
[origin: WO2008051291A2] Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric Nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.

IPC 8 full level
A61K 47/48 (2006.01); **A61K 9/14** (2006.01); **A61K 9/51** (2006.01); **A61K 31/195** (2006.01); **A61K 31/198** (2006.01); **A61K 31/765** (2006.01); **A61K 31/78** (2006.01); **A61P 9/00** (2006.01); **A61P 9/10** (2006.01); **A61P 17/02** (2006.01)

CPC (source: EP)
A61K 47/55 (2017.07); **A61K 47/551** (2017.07); **A61K 47/58** (2017.07); **A61K 47/59** (2017.07); **A61K 47/593** (2017.07); **A61K 47/60** (2017.07); **A61K 47/61** (2017.07); **A61K 47/6923** (2017.07); **A61K 47/6929** (2017.07); **A61K 47/6935** (2017.07); **A61K 47/6937** (2017.07); **A61K 47/6939** (2017.07); **A61K 49/0008** (2013.01); **A61P 9/00** (2017.12); **A61P 9/10** (2017.12); **A61P 17/02** (2017.12); **A61P 35/00** (2017.12); **B82Y 5/00** (2013.01)

Citation (search report)
See references of WO 2008051291A2

Citation (examination)
• WO 9640048 A2 19961219 - KAROBIO AB [SE], et al
• YALCIN M ET AL: "Tetraiodothyroacetic Acid (Tetrac) and Nanoparticulate Tetrac Arrest Growth of Medullary Carcinoma of the Thyroid", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, THE ENDOCRINE SOCIETY, US LNKD- DOI:10.1210/JC.2009-1926, vol. 95, no. 4, 1 April 2010 (2010-04-01), pages 1972 - 1980, XP009137367, ISSN: 0021-972X
• GLINSKII A B ET AL: "Modification of survival pathway gene expression in human breast cancer cells by tetraiodothyroacetic acid (tetrac)", CELL CYCLE, XX, GEORGETOWN, TX, US, vol. 8, no. 21, 1 November 2009 (2009-11-01), pages 3562 - 3570, XP009137365, ISSN: 1538-4101
• DAVIS PAUL J ET AL: "Molecular mechanisms of actions of formulations of the thyroid hormone analogue, tetrac, on the inflammatory response.", ENDOCRINE RESEARCH 2013, vol. 38, no. 2, 2013, pages 112 - 118, ISSN: 1532-4206
• BOEHNCKE WOLF-HENNING: "Etiology and Pathogenesis of Psoriasis.", RHEUMATIC DISEASES CLINICS OF NORTH AMERICA NOV 2015, vol. 41, no. 4, November 2015 (2015-11-01), pages 665 - 675, ISSN: 1558-3163
• BOGUSLAW NEDOSZYTKO ET AL: "Chemokines and cytokines network in the pathogenesis of the inflammatory skin diseases: atopic dermatitis, psoriasis and skin mastocytosis", POSTĘPY DERMATOLOGII I ALERGOLOGII = ADVANCES IN DERMATOLOGY AND ALLERGOLOGY, vol. 2, 1 January 2014 (2014-01-01), POLAND, pages 84 - 91, XP055268668, ISSN: 1642-395X, DOI: 10.5114/pdia.2014.40920

Cited by
CN108635589A

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

Designated extension state (EPC)
AL BA HR MK RS

DOCDB simple family (publication)
WO 2008051291 A2 20080502; WO 2008051291 A3 20081224; CA 2648243 A1 20080502; CA 2648243 C 20151222; EP 2018186 A2 20090128

DOCDB simple family (application)
US 2007009026 W 20070411; CA 2648243 A 20070411; EP 07867073 A 20070411